ccamire's  Instablog

Send Message
I work for the pharma industry for 20 years and for the last 10 years I have worked as a sell-side analyst and investment banker in healthcare
  • IntelGenx - Moving To The Next Stage 8 comments
    Oct 10, 2012 5:02 AM | about stocks: IGXT

    The Event- Forfivo XL is now officially launched in the US

    Forfivo XL is the first high-dose 450mg bupropion with a controlled release delivery formulation (once-a-day). The event is important for IntelGenx because it is first major product launch in the US market. I don't expect any revenues outside the US.

    Forfivo XL is certainly not a generic and therefore many people will be happy to know that. I also believe the recent decision by the FDA to pull the Teva/ Impax generic Wellbutrin XL 300mg from the market for non-bioequivalence could be a positive to Forfivo XL. I expect doctors to be more cautious in prescribing generics because they may not provide the expected benefits for the patients. There are certain drugs that people don't want to play with and they relate to CNS drugs. In addition the FDA is being more aggressive on closing down internet pharmacies because they are selling a number of non-equivalent dosages. Therefore bringing a novel drug such as Forfivo XL 450mg will be appealing for people who will expect quality. The Forfivo XL single dose bioequivalence study completed some time ago proved to be bio-equivalent to 3 Wellbutrin XL150mg tablets once daily. This will be important for physicians who don't want to offer high doses to patients and expect compliance. In many cases, patients stop taking medications because they feel they are taking too many pills every day. In a recent study conducted in the US, 49% said they had forgotten to take a prescribed medicine; 29% had stopped taking a medicine before the supply ran out; and 24% had taken less than the recommended dosage. So it is better to take 1 pill than 3 pills.

    The Big Picture

    According to various market research companies, the US depression therapeutics market is roughly US$4bn in 2011 and is expected to grow at double digit reaching US$8bn by 2018. Even though there are 20 different molecules being sold by many companies, doctors are usually concerned about what they know and have experience with. For Forfivo, the name of the game to succeed in the US is to show patient benefit at an attractive pricing. While we estimate that ~80% of the market will be reimbursed with private insurance, we estimate the balance to be covered by Medicaid and Medicare with a small portion of paying patients. This implies a pricing strategy is of critical importance in this crowdie market. On a efficacy basis, comparative studies have demonstrated the equivalency of bupropion to Paxil (paroxetine), Lexapro, Zoloft and Prozac as antidepressants. Given its favorable efficacy and safety properties, bupropion still sells in large quantities: in 2011, total branded and generic sales totaled US$745m or about 3% of total prescriptions in volume. Bupropion has also lower side effects than most popular depression drugs. Forfivo is likely to be targeting the highest prescribers among the 45,000 psychiatrists in the US. Given that probably a portion of patients will likely require at least 450mg of buprorion, the primary market is slightly reduced. Don't expect lots of revenues in 2012 but rather 2013 where they will be finally profitable. I have seen recent market studies that also exemplifies demand by psychiatrists to use a higher dose drug when available. In the case of depression, a good portion of patients do require more than 450mg of Wellbutrin XL for an everyday treatment. In one study that I have seen, 98% of psychiatrists felt that there was a need for an higher dose because it increase compliance and 40% would recommend Wellbutrin XL because that is the drug they prefer to use for treating MDD.

    The Marketing partner

    Edgemont Pharmaceuticals, a private company, may be not a household name but with close to 200 reps and senior management with big Pharma experience will be targeting specialists treating depression. With a recent financing of $15m completed earlier in the year and growing revenues from their first product launched late last year, also a CNS product (high-dose fluoxetine or Prozac), we think this commercial strategy could be really effective.

    One Product Valuation Is Higher Than The Whole Company

    Just for Forfivo, we estimate the NPV at $58m, so how do I come up with this number. First let's look at the agreement. IntelGenx received a US$1m upfront payment +another US$4m for the launch + commercial milestones of up to $23.5m (if they achieve certain levels) + tiered double-digit royalties.

    What could be the peak sales be in three years:

    Already 1.5-2.0m patients on Bupropion

    X 15-25% on high doses

    X $600-900 yearly price range

    X 20-25% market share

    X18-22% royalty range

    = Median range for revenues of ~$70m and royalty revenues for IGXT of $15m.

    NPV= $58m using a 15% discount rate

    For a company with a market cap of $25m and lots of undiscovered value, it's worth looking at.

    Investment thesis

    I think the next $100m product that is expected to be launched in 2014 is the reformulated branded drug Maxalt (Merck) using the proprietary and unique IntelGenx' oral film. Convenience and rapid onset of action will certainly be attractive not only for current migraine patients using Maxalt but also patients on other triptans (Imitrex, Relpak, Zomig, etc...) which control the US$4bn worldwide market. The drug is already partnered with RedHill Biopharma, so the financial risk is very low.

    The Stock Price

    Low business risk, diversified portfolio and the company should be profitable one year after the launch of Forfivo XL.

    IGXT has also 9 other reformulated human drugs in development to hit the market between now and 2016. Compared to an approval rate of ~30% for New Chemical Entities (preclinical to market), reformulated drugs get approved in more than 90% of cases. All of the drugs are developed based with two clinical trials: pilot and pivotal bioavailability, which usually cost less than $1m each. Sorry I forgot to mention, maybe we should add the other animal drugs being developed for which investors have not pegged any value but I don't want to overwhelmed our readers. I would expect the stock price continue to improve given the positive technical trends.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: IGXT
Back To ccamire's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (7)
Track new comments
  • garypalys
    , contributor
    Comments (122) | Send Message
    Thanks for a great article, but you failed to mention the collaboration with PAR Pharma... Judging by the October 2012 Intelgenx presentation, the deal looks to be huge! We still don't know what the drug is, but they are supposed to be doing a regulatory filing on it either this quarter or 1st. quarter 2013
    10 Oct 2012, 04:27 PM Reply Like
  • Jpuddleduck
    , contributor
    Comments (2) | Send Message
    look at the IGXT presentation. IGXT are forecasting like $5M in revenue for FORFIVO???


    You said it yourself big pharma isn't interested in reformulations.


    Any news on the Par product. this looks promising?
    11 Oct 2012, 10:05 AM Reply Like
  • garypalys
    , contributor
    Comments (122) | Send Message
    Take a look at their October 2012 presentation and you will see on slide 18 that the PAR deal appears to be quite large. This is the first peak that we have at what the revenue might look like...

    13 Oct 2012, 12:47 PM Reply Like
  • ccamire
    , contributor
    Comments (39) | Send Message
    Author’s reply » I dont know you keep talking about my comment on "big pharma" not interested in reformulations. IntelGenx is partnering reformulated drugs with specialty pharma and novel drugs with bigger companies. I would assume that Par is working on a NOVEL drug with IGXT, but i am not sure.


    I have great expectations for Forfivo but even greater for the migraine drug because this reformulation is very novel and helpful for patients. I think we should expect great revenues if the company can manage a decent cost of sales, which I am not aware.It will be key to its commercial success.
    11 Oct 2012, 12:22 PM Reply Like
  • Jpuddleduck
    , contributor
    Comments (2) | Send Message
    IGXT's forecasts in the presentation are saying they are going to earn a lot less than what you say above. Why do you think that the IGXT forecasts are wrong. And if big pharma has no interest in reformulations don't that mean that reformulations are small fish. Just cause its novel don't mean its good. look at silenor.
    11 Oct 2012, 05:31 PM Reply Like
  • ccamire
    , contributor
    Comments (39) | Send Message
    Author’s reply » First IGXT need to provide conservative forecast to investors because the stock would get slammed if they dont meet the expectations.


    Second. There is difference between good drugs and potential revenues. Reformulations are in most cases much safer for patients because companies like IGXT have worked to "optimized" the drug. However the potential is much less than the original drug because the commercial need to convince physicians, pharmacists and patients to switch. Sometimes, physicians are conservative and don't want to change medications. Therefore the potential is a fraction of the total drug unless there is expansion within the market or new uses. Big Pharma are not interested because they sell few drugs thru their salesforece. Did you know that more than 80% of drug at big Pharma are not even promoted by nobody. They were in the past and now they are not. Unless you can show potential of >$500m, all big Pharma will not promote reformulated drugs.
    Lastly I did looked quickly Silenor. Their problem with their drug is that the product does not fill an unmet medical need. There are already a very popular drug being sold to get you to sleep. Silenor is mostly focused on people on long term medications which is a fraction of the market. Plus Somaxon has no other visible product in development while IGXT has 10 other drugs that could be on the market within the next 4 years. That is quite different.
    12 Oct 2012, 12:06 PM Reply Like
  • railroadman
    , contributor
    Comments (53) | Send Message
    Great explantation. Thanks
    9 Jan 2014, 07:18 PM Reply Like
  • garypalys
    , contributor
    Comments (122) | Send Message
    I know this is old now, but that was a great response Claude!
    6 Jan 2013, 01:46 PM Reply Like
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.